Efficacy of Glibenclamide in Maturity-Onset Diabetics as Maintenance Therapy

Abstract

Results of 75 patients of maturity-onset, nonketotic diabetes who have been maintained on glibenclamide for a period ranging from 6 to 42 months have been analyzed. Ninety-five percent of the newly diagnosed patients administered glibenclamide as the initial drug showed the best overall response. In 22 out of 43 patients with secondary failures on conventional sulphonylureas, satisfactory control was achieved by glibenclamide alone or in combination with biguanides. It was of help also in changing over from insulin therapy to oral drugs in 5 out of 12 such cases. No serious side-effects were encountered during follow-up of more than three years. Scope of glibenclamide in reference to management of diabetes in different situations is discussed.

Key words

Glibenclamide - Secondary Failure - Sulphonylureas - Toxicity - Side Effects